ATE258175T1 - 3-thiazol-4-yl-pyrrolidinderivate als amp- spezifische phosphodiesterase-inhibitoren - Google Patents

3-thiazol-4-yl-pyrrolidinderivate als amp- spezifische phosphodiesterase-inhibitoren

Info

Publication number: ATE258175T1
Authority: AT; Austria
Prior art keywords: thiazole; phosphodiesterase inhibitors; pyrrolidine derivatives; specific phosphodiesterase; disclosed
Prior art date: 1999-12-23

Application number

AT00992525T

Other languages

English (en)

Inventor

Kerry W Fowler

Joshua Odingo

Original Assignee

Icos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-23

Filing date

2000-11-28

Publication date

2004-02-15

2000-11-28 Application filed by Icos Corp filed Critical Icos Corp

2004-02-15 Application granted granted Critical

2004-02-15 Publication of ATE258175T1 publication Critical patent/ATE258175T1/de

Links

RWTPTYUXLDJACB-UHFFFAOYSA-N 4-pyrrolidin-3-yl-1,3-thiazole Chemical class C1NCCC1C1=CSC=N1 RWTPTYUXLDJACB-UHFFFAOYSA-N 0.000 title 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
210000003169 central nervous system Anatomy 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Otolaryngology (AREA)

AT00992525T 1999-12-23 2000-11-28 3-thiazol-4-yl-pyrrolidinderivate als amp- spezifische phosphodiesterase-inhibitoren ATE258175T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17195099P	1999-12-23	1999-12-23
PCT/US2000/042293 WO2001046184A1 (en)	1999-12-23	2000-11-28	3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
ATE258175T1 true ATE258175T1 (de)	2004-02-15

Family

ID=22625761

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00992525T ATE258175T1 (de)	1999-12-23	2000-11-28	3-thiazol-4-yl-pyrrolidinderivate als amp- spezifische phosphodiesterase-inhibitoren

Country Status (12)

Country	Link
US (2)	US6313156B1 (de)
EP (1)	EP1242415B1 (de)
JP (1)	JP2003518116A (de)
CN (1)	CN1222523C (de)
AT (1)	ATE258175T1 (de)
AU (1)	AU778593B2 (de)
CA (1)	CA2395114C (de)
DE (1)	DE60007897T2 (de)
DK (1)	DK1242415T3 (de)
ES (1)	ES2215093T3 (de)
PT (1)	PT1242415E (de)
WO (1)	WO2001046184A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6313156B1 (en) *	1999-12-23	2001-11-06	Icos Corporation	Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
EP1348701A1 (de) *	2002-03-28	2003-10-01	Warner-Lambert Company LLC	2,4-disubstituierte Thiazol-5-yl-Amine als PDE7-Inhibitoren
CA2506949A1 (en) *	2002-11-27	2004-06-10	Altana Pharma Ag	Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
EP1613265A4 (de) *	2003-04-04	2007-02-14	Merck & Co Inc	Di-aryl-substituierte pyrrol-modulatoren von metabotropischem glutamat-rezeptor-5
WO2005018556A2 (en)	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
RU2006105101A (ru)	2003-08-27	2007-10-10	3М Инновейтив Пропертиз Компани (US)	Арилокси и арилалкиленокси замещенные имидазохинолины
WO2005023190A2 (en)	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
JPWO2005026132A1 (ja) *	2003-09-17	2007-11-08	日本新薬株式会社	ホスホジエステラーゼのｃＡＭＰ基質特異的阻害剤
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US8871782B2 (en)	2003-10-03	2014-10-28	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
CA2545774A1 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
US8598192B2 (en)	2003-11-14	2013-12-03	3M Innovative Properties Company	Hydroxylamine substituted imidazoquinolines
AR046781A1 (es)	2003-11-25	2005-12-21	3M Innovative Properties Co	Derivados de imidazoquinolinas. composiciones farmaceuticas.
WO2005066170A1 (en)	2003-12-29	2005-07-21	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005067500A2 (en) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Enhancement of immune responses
CA2551399A1 (en)	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en)	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en)	2004-06-15	2005-12-29	3M Innovative Properties Company	Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en)	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US8026366B2 (en)	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
WO2006065280A2 (en)	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
AU2005326708C1 (en)	2004-12-30	2012-08-30	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1831226B1 (de)	2004-12-30	2012-08-08	3M Innovative Properties Company	Chirale tetracyklische verbindungen, die interferon biosyntheze induzieren
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
CA2597587A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP2275096A3 (de)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
US7906506B2 (en)	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008030651A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2196465A1 (de)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea-Derivate als PDE4 Hemmern
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (de)	2009-02-27	2010-09-08	Almirall, S.A.	Neuartige Tetrahydropyrazol[3,4-c]isochinolin-5-amin-Derivate
EP2380890A1 (de)	2010-04-23	2011-10-26	Almirall, S.A.	Neue 7,8-Dihydro-1,6-Naphthyridin-5(6H)-on-Derivate als PDE4 Inhibitoren
EP2394998A1 (de)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl Derivate als PDE4 Inhibitoren
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4298743A (en)	1979-09-11	1981-11-03	Merck & Co., Inc.	4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
EP0259085B1 (de) *	1986-08-29	1991-08-21	Pfizer Inc.	2-Guanidino-4-aryl-thiazole für die Behandlung von peptischen Geschwüren
US5026713A (en)	1989-08-29	1991-06-25	Monsanto Company	1,3-dideoxy-3-fluoronojirimycin which inhibits glycosidase activity
US5665754A (en)	1993-09-20	1997-09-09	Glaxo Wellcome Inc.	Substituted pyrrolidines
CA2143143A1 (en)	1994-03-08	1995-09-09	Toshihiko Tanaka	3-phenylpyrrolidine derivatives
US5998428A (en)	1995-05-31	1999-12-07	Smithkline Beecham Corporation	Compounds and methods for treating PDE IV-related diseases
US6313156B1 (en) *	1999-12-23	2001-11-06	Icos Corporation	Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors

2000
- 2000-11-27 US US09/723,091 patent/US6313156B1/en not_active Expired - Fee Related
- 2000-11-28 DK DK00992525T patent/DK1242415T3/da active
- 2000-11-28 DE DE60007897T patent/DE60007897T2/de not_active Expired - Fee Related
- 2000-11-28 CA CA002395114A patent/CA2395114C/en not_active Expired - Fee Related
- 2000-11-28 EP EP00992525A patent/EP1242415B1/de not_active Expired - Lifetime
- 2000-11-28 WO PCT/US2000/042293 patent/WO2001046184A1/en not_active Ceased
- 2000-11-28 AU AU45077/01A patent/AU778593B2/en not_active Ceased
- 2000-11-28 ES ES00992525T patent/ES2215093T3/es not_active Expired - Lifetime
- 2000-11-28 CN CNB008191212A patent/CN1222523C/zh not_active Expired - Fee Related
- 2000-11-28 AT AT00992525T patent/ATE258175T1/de not_active IP Right Cessation
- 2000-11-28 JP JP2001547094A patent/JP2003518116A/ja active Pending
- 2000-11-28 PT PT00992525T patent/PT1242415E/pt unknown
2001
- 2001-09-18 US US09/954,934 patent/US6486186B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6313156B1 (en)	2001-11-06
CA2395114C (en)	2006-07-11
EP1242415B1 (de)	2004-01-21
US6486186B2 (en)	2002-11-26
DE60007897D1 (de)	2004-02-26
CA2395114A1 (en)	2001-06-28
JP2003518116A (ja)	2003-06-03
US20020042435A1 (en)	2002-04-11
AU4507701A (en)	2001-07-03
AU778593B2 (en)	2004-12-09
PT1242415E (pt)	2004-05-31
DK1242415T3 (da)	2004-06-01
CN1222523C (zh)	2005-10-12
ES2215093T3 (es)	2004-10-01
CN1434823A (zh)	2003-08-06
DE60007897T2 (de)	2004-11-04
WO2001046184A1 (en)	2001-06-28
EP1242415A1 (de)	2002-09-25

Legal Events

Date

Code

Title

Description

2004-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1242415

Country of ref document: EP

2009-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60007897D1 (de)	2004-02-26	3-thiazol-4-yl-pyrrolidinderivate als amp-spezifische phosphodiesterase-inhibitoren
EE05087B1 (et)	2008-10-15	Pürrolidiini derivaadid tsüklilise AMP-spetsiifilise fosfodiesteraasi inhibiitoritena
MXPA02006206A (es)	2004-02-26	Pirrolidinas que inhiben la pde camp-especifica.
NO952398L (no)	1995-06-16	Pyrrolpyrimidiner som CRF antagonister
ATE349209T1 (de)	2007-01-15	Naphthyridine derivate, ihre herstellung und ihre anwendung als phosphodiesterase isoenzyme 4 (pde4) inhibitoren
ATE194593T1 (de)	2000-07-15	3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
MY135766A (en)	2008-06-30	Quinolinones and naphthyridinones for treating inflammatory diseases
ATE340796T1 (de)	2006-10-15	Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
AU2002220715A1 (en)	2002-06-03	Indolsulfonyl compounds useful in the treatment of cns disorders
NO20043085L (no)	2004-07-13	Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DK1339406T3 (da)	2004-09-27	Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DE60018470D1 (de)	2005-04-07	Cyclische amp spezifische phosphodiesterase inhibitoren
DE60103856D1 (de)	2004-07-22	Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
ATE367380T1 (de)	2007-08-15	Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
HRP20050572A2 (en)	2006-08-31	Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
PT1294729E (pt)	2005-01-31	2-aminoalquil-tieno[2,3-d]pirimidinas
DK1017377T3 (da)	2002-03-04	Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande